Form 10-Q CATALYST PHARMACEUTICALS For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Catalyst Pharmaceutical Partners (CPRX) PT Raised to $31 at Citi
August 9, 2024 4:56 AM EDTCiti analyst Samantha Semenkow raised the price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) to $31.00 (from $27.00) while maintaining a Buy rating.
The analyst comments "There was a lot to like in Catalysts 2Q print, as we outlined in our initial take, with... More
